left colon cancer, rectal cancer
Conditions
Interventions
mOAMBP group(sodium picosulfate hydrate + Kanamycin, Metronidazole) (combined drug) Kanamycin 250mg 12C x3(after lunch, dinner, and before bedtime) and Metronidazole 250mg 6C x3(after lunch, dinne
Sponsors
Tokyo Medical and Dental University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients undergoing resection for rectal cancer or left-sided colon cancer, with or without diverting ileostomy 2) Patients undergoing DST or transanal bowel anastomosis 3) Patients between 20 and 85 years old 4) Patients with a performance status (ECOG) of 0 or 1 5) Patients who meet the following criteria for laboratory tests within 30 days of enrollment 1. White blood cell: WBC = 3000, or 3000<WBC<10000/ul 2. Neutrophils: Neu = 1500, Neu > 1500/ul 3. Hemoglobin: Hb = 9.0 or > 9.0g/dl 4. Platelet: Plt = 70000 or > 70000/ul 5. Total Bilirubin: T.Bil = 1.5 or < 1.5mg/dl 6. AST: AST = 100 or < 100IU/l 7. ALT: ALT = 100 or < 100IU/l 8. Albumin: Alb = 2.5 or > 2.5g/dl 6) Patients who have given informed consent
Exclusion criteria
Exclusion criteria: 1) Patients who need emergency surgery 2) Patients with preoperative intestinal obstruction 3) Patients with suspected active bacterial infection (abscess formation, colon cancer perforation, etc.) 4) Patients who are pregnant or have the potential to become pregnant 5) Diabetic patients with poor control (HbA1c 8.0 or < 8.0) 6) Patients who are allergic to drugs used in the study (macrogol, sodium picosulfate hydrate, kanamycin, metronidazole) 7) Patients undergoing neoadjuvant radiotherapy or neoadjuvant chemotherapy 8) Patients with colostomy or ileostomy 9) Patients who have not given informed consent 10) Patients who are judged by the principal investigator or the investigator to be ineligible for the safe conduct of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of SSI | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of postoperative complications excluded SSI, operation time, extent of bleeding, postoperative hospital stay, intraoperative adverse events, degree of patient burden, degree of intraoperative intestinal dilation | — |
Countries
Japan
Contacts
Public ContactSodai Arai
Tokyo Medical and Dental University Graduate School of Medicine Department of Gastrointestinal Surgery
Outcome results
None listed